Saturday, October 31, 2026

GBP/EUR Bullish By 1% In The Last 21 Sessions

GBP/EUR Bullish By 1% In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.89% for the last 21 sessions. At 15:12 EST on Sunday, 28 May, GBP/EUR (GBPEUR) is $1.15.

GBP/EUR's yearly highs and lows, it's 6.381% up from its 52-week low and 4.054% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.05%, a positive 0.13%, and a positive 0.26%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.15% (last week), 0.26% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Friday, 26 May, "At the time of writing, EUR/USD is treading water at around 1.0730, modestly flat on the day."
  • Eur/usd to stay soft near 1.0700/0720 – ING. According to FXStreet on Friday, 26 May, "There were reports in the market yesterday of some upside interest in EUR/USD going through the FX options market. ", "Expect EUR/USD to stay soft near 1.0700/0720 and perhaps take a decisive turn on the release of the US inflation data."
  • Eur/usd: switch from recovery to sustainably lower levels could occur around turn of the year – commerzbank. According to FXStreet on Friday, 26 May, "In the coming months, EUR/USD is likely to strengthen because the ECB's monetary policy is likely to be more hawkish in the near future and therefore more attractive from a currency market perspective than that of the Fed. ", "We suspect that the turnaround in the EUR/USD exchange rate could come around the turn of the year."
  • Eur/usd to trade above 1.30 again once ECB rates move higher than fed rates – socgen. According to FXStreet on Friday, 26 May, "Economists at Société Générale expect the EUR/USD pair to race higher driven by relative natural rates.", "EUR/USD almost broke above 1.50 in that cycle and while that seems inconceivable, we're more optimistic than we have been for a while, that we'll see EUR/USD above 1.30 again, once the war in Ukraine and Europe's energy troubles are behind us."
  • Eur/usd price analysis: euro rebounds to target 1.0750 amid persistent bears ahead of key US data. According to FXStreet on Friday, 26 May, "Even if the EUR/USD buyers manage to cross the 1.0765 hurdle, the 100-day Exponential Moving Average (EMA) of around 1.0780 can act as the last defense of the EUR/USD bears before directing it to the mid-month peak surrounding 1.0900.", "Overall, EUR/USD remains on the bear's radar despite the latest corrective bounce."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com